Musterschreiben Impfung im Gesundheitswesen
Erarbeitet von Prof.Dr.jur. Martin Schwab, NRW-Spitzenkandidat der Basis
Martin Schwab - Profil bei abgeordnetenwatch.de
Sehr geehrte/r Herr/Frau (Name des Arbeitgebers oder der zuständigen Ansprechperson beim Arbeitgeber)

Sie haben mit Schreiben vom /auf einer Personalversammlung am /in einem am geführten Gespräch angekündigt, dass Sie mich ab dem 16.3.2022 weder weiter beschäftigen noch weiterbezahlen werden, wenn ich bis dahin keinen Nachweis einer Impfung gegen SARS CoV-2 vorgelegt habe.

⦁ Wirksame Einwilligung unter Druck unmöglich

Nach wie vor bin ich demgegenüber fest entschlossen, mich einer solchen Impfung nicht zu unterziehen. Und ich kann Sie nur davor warnen, den Druck „Impfung oder Kündigung/unbezahlte Freistellung“ aufrechtzuerhalten. Denn Sie begeben sich juristisch auf heikles Terrain.

Ich mache Sie nämlich hiermit darauf aufmerksam, dass ich unter dem Druck, unter den Sie mich setzen, überhaupt keine wirksame Impfeinwilligung erteilen kann. Kein Arzt der Welt kann mich jetzt noch impfen, ohne dass er sich seinerseits strafbar und schadensersatzpflichtig macht.

Für die Impfung gegen SARS CoV-2 gelten die gleichen Grundsätze wie für jeden anderen medizinischen Eingriff: Es handelt sich um eine tatbestandsmäßige Körperverletzung, die nur rechtmäßig ist, wenn und weil sie von der Einwilligung des Patienten gedeckt ist. Eine wirksame Einwilligung ist nur dann gegeben, wenn (1.) dem Eingriff eine ordnungsgemäße Aufklärung über Nutzen und Risiken vorausgegangen ist und (2.) die Einwilligung nicht unter Druck erteilt worden ist. Die Drohung, die Grundlage der Finanzierung meines Lebensunterhalts zu verlieren, entfaltet eine so starke erhebliche Druckwirkung, dass eine wirksame Impfeinwilligung unter diesen Umständen ausgeschlossen ist.

⦁ Haftungsrechtliche Konsequenzen

Da Sie mich vor die Alternative stellen, mich entweder impfen zu lassen oder ab dem 16.3.2022 ohne Bezahlung dazustehen, wären Sie, wenn ich mich denn unter diesem Druck impfen ließe, unter dem Gesichtspunkt der mittelbaren Täterschaft (§ 25 Abs. 1, 2. Alt. StGB) persönlich dafür verantwortlich, dass an mir in Gestalt der COVID-19-Impfung eine solche Körperverletzung begangen wird. Nun legen Sie es mit dem Druck, den Sie auf mich ausüben, auf genau eine solche Impfung und damit auf eben diese Körperverletzung an. Damit verwirklicht die von Ihnen ausgesprochene Drohung den Tatbestand eines strafbaren Versuchs der gefährlichen Körperverletzung (§§ 224 Abs. 1 Nr. 1 und 5, Abs. 2, 22 StGB). Außerdem verwirklicht Ihre Drohung, dass ich meinen Arbeitsplatz verliere, wenn ich mich nicht impfen lasse, den Tatbestand der versuchten Nötigung (§§ 240 Abs. 1, Abs. 2, 22 StGB). Bei allen genannten Vorschriften handelt es sich um Schutzgesetze im Sinne von § 823 Abs. 2 BGB. Sie haften damit persönlich für alle Schäden, die mir dadurch entstehen, dass Sie versuchen, mich mit existenzbedrohendem Druck zur Impfung zu drängen.

Und sogar noch schwerere Straftatbestände können – jeweils in der Form des strafbaren Versuchs – erfüllt sein. Die Impfungen sind nämlich entgegen verbreiteter Berichterstattung in den Altmedien keinesfalls sicher. Die Schäden durch die COVID-Impfungen können vielmehr beträchtliche Ausmaße annehmen; es wäre, wenn ich mich denn impfen ließe, sogar möglich, dass ich an der Impfung sterbe. Näheres entnehmen Sie bitte dem aktuellen Sicherheitsbericht des Paul-Ehrlich-Instituts:
pei.de/…/newsroom/dossiers/sicherheitsberichte/sicherheits bericht-27-12-20-bis-30-11-21.pdf? blob=publicationFile&v=7.

Mittlerweile sind die hoch gefährlichen und teilweise tödlichen Impfnebenwirkungen in mehr als 1.000 wissenschaftlichen Studien beschrieben (siehe die Auflistung in Anlage 1) – und täglich kommen neue Studien dazu.

Es erscheint immer schwerer begreiflich, wie viel wissenschaftliche Evidenz die Menschheit noch benötigt, um zu erkennen, dass die in Deutschland zugelassenen COVID-Impfstoffe massive gesundheitliche Schäden anrichten.
Es häufen sich zudem seit dem Impfstart Medienberichte, wonach Menschen nach der Impfung „plötzlich und unerwartet“ von uns gehen oder jedenfalls schwerste Schäden davontragen:

Gepiekst und verstorben – „Plötzlich und unerwartet“ › Jouwatch

Confirmed Media Reports of Covid-19 Vaccine Severe Adverse Events and Deaths

Besonders erschütternd ist der am 24.1.2022 veröffentlichte Selbstbericht eines Mitarbeiters der Mainzer Stadtverwaltung, der nach der Impfung unter wochenlangen massiven Schmerzen litt und schließlich mit knapper Not einen ischämischen Schlaganfall überlebte:
„Seit meiner Impfung ist nichts mehr, wie es war“

Sehenswert ist auch die zweiteilige Dokumentation des Schicksals Impfgeschädigter auf SERVUS.TV:
Teil 1 (19.1.2022): Im Stich gelassen – die COVID-Impfopfer: servustv.com/aktuelles/v/aa1uhra88dp5llzqs7cp/

Teil 2 (27.1.2022): COVID-Impfopfer – Geschädigte, die es nicht geben darf: servustv.com/aktuelles/v/aa2fcz9y1l5c4uuygsjz/

Sämtliche dieser Berichte zeigen, dass die Betroffenen (wohlgemerkt: das sind jene, die es überlebt haben!) nicht nur schwerstem Leid ausgesetzt sind, sondern von den relevanten Akteuren auch noch verhöhnt werden: von Ärzten, die vor dem Zusammenhang mit der Impfung geflissentlich die Augen verschließen, und vor Behörden, die sich ungeachtet der schweren Nebenwirkungen allen Ernstes weigern, für weitere Impfungen eine Kontraindikation anzuerkennen.

Selbst den Herstellern der COVID-Impfstoffe bleiben die fatalen Nebenwirkungen nicht verborgen. Auf gerichtliche Anordnung musste die US-amerikanische Food And Drugs Administration (FDA) interne und als vertraulich eingestufte Dokumente herausgeben, die sich auf den Pfizer/BioNTech- Impfstoff „Comirnaty“ beziehen – jenen Impfstoff also, der in Deutschland mit Abstand am häufigsten verabreicht wird. Aus einem dieser Dokumente geht hervor, dass Pfizer bereits bis Ende Februar 2021, also keine drei Monate nach dem Impfstart, von 1.223 (!) Fällen Kenntnis erlangt hatte, in denen die Impfung einen tödlichen Ausgang genommen hatte:
phmpt.org/…uploads/2021/11/5.3.6-postmarketing-experience.pdf (siehe dort Tabelle Seite 7).

Wollen Sie den Fortbestand meines Arbeitsverhältnisses allen Ernstes davon abhängig machen, dass ich in Gestalt der COVID-Impfung mein Leben oder aber zumindest schwerste bleibende Gesundheitsschäden riskiere?

Verlautbarungen von Politikern, regierungstreuen Medien, Ärztekammern und Berufsverbänden, die COVID-Impfungen seien sicher, entbehren jeglicher Grundlage. Aussagen etwa des Inhalts, es gebe keinen Grund, sich nicht impfen zu lassen, sind durch die Studienlage klar widerlegt. Soweit „Impfverweigerer“ gar zum Feindbild stilisiert und z. B. als Sozialschädlinge, als asoziale Trittbrettfahrer oder als Schuldige an der Fortdauer der Corona-Maßnahmen beschimpft werden, handelt es sich um faktenferne Propaganda, die nur darauf abzielt, durch Ausgrenzung weiteren psychischen Druck zu erzeugen.

⦁ Neueste Erkenntnisse: Unterschiedlich dosierte Chargen

Eine wirksame Impfeinwilligung kann ich darüber hinaus deshalb nicht abgeben, weil jeder, der sich gegen SARS CoV-2 impfen lässt, an einer experimentellen klinischen Studie teilnimmt, ohne nach seiner Einwilligung gefragt worden zu sein. Es gibt nämlich mittlerweile erdrückende Beweise dafür, dass die Impfstoffhersteller Pfizer/BioNTech, Moderna und Johnson & Johnson zielgerichtet Chargen mit unterschiedlichen Inhalten in den Verkehr bringen.

Ablesen kann man dies insbesondere anhand der Daten aus dem Vaccine Adverse Events Reporting System (VAERS) in den USA. Die Nebenwirkungsrisiken sind in einigen Chargen dramatisch erhöht. Was mit diesen unterschiedlichen Inhalten bezweckt wird, gilt es derzeit zu ermitteln.

Nicht auszuschließen ist, dass die Hersteller derzeit ausprobieren, bei welcher Dosierung sich welche (Neben-)Wirkungen einstellen; ebenso denkbar ist, dass die Hersteller unterschiedliche Hilfsstoffe (Adjuvantien) einsetzen und deren Wirkung beobachten wollen. Näheres entnehmen Sie bitte dem als Anlage 2 beigefügten Medienbericht.

Insbesondere die Hypothese eines Dosis-Experiments wäre, wenn sie sich bewahrheiten sollte, fatal. Untersuchungen zur Adjustierung der Dosis hätten nämlich eigentlich längst in einer klinischen Phase-II-Studie angestellt werden müssen, also bevor die COVID-Impfstoffe überhaupt auch nur eine bedingte Zulassung erhielten. Aber selbst wenn es sich nicht um ein Dosis-Experiment handeln sollte: Allein schon die Tatsache, dass nicht in allen Impfstoff-Flaschen dasselbe enthalten ist, ist hochgradig kriminell. Es ist schon schlimm genug, dass ich von Ihnen zur Einwilligung in eine experimentelle Impfung gezwungen werden soll. Es ist aber noch etwas völlig anderes, ob ich in eine Impfung oder aber in die Teilnahme an einer klinischen Studie einwillige. Letzteres kommt für mich unter gar keinen Umständen in Betracht. Ich weigere mich strikt, meinen Körper der Pharmaindustrie als Versuchsobjekt zur Verfügung zu stellen!

⦁ Keine Rechtfertigung der Impferpressung durch § 20a IfSG

Ihre Drohung, mein Arbeitsverhältnis ohne COVID-Impfung zu beenden oder mich unbezahlt freizustellen, lässt sich auch nicht mit dem Hinweis rechtfertigen, Sie hätten lediglich dem Normbefehl des § 20a IfSG Folge geleistet. Richtig ist vielmehr, dass Sie mich weiterbeschäftigen dürfen, bis das Gesundheitsamt ein Betretungsverbot ausspricht. Dies haben Juristen des Netzwerks Kritische Richter und Staatsanwälte in zwei Beiträgen näher herausgearbeitet:
Weiterarbeit im Gesundheitssektor trotz fehlender Impfung möglich? – „Kann-Regelung“ in § 20a Abs. 5 Infektionsschutzgesetz lässt Gesundheitsämtern Spielraum, Pflegekatastrophe abzuwenden moeglich-kann-regelung-in-%c2%a7-20a-abs-5-infektionsschutzgesetz-laesst-gesundheitsaemtern- spielraum-pflegekat/.

Ist die Weiterbeschäftigung eines Arbeitnehmers ohne Immunitätsnachweis im Gesundheitswesen ab dem 16. März 2022 für den Arbeitgeber eine Ordnungswidrigkeit, solange seitens des Gesundheitsamtes kein Betretungsverbot ausgesprochen wird und der Arbeitnehmer schon vor dem 16. März 2022 in der Einrichtung oder dem Unternehmen beschäftigt war? immunitaetsnachweis-im-gesundheitswesen-ab-dem-16-maerz-2022-fuer-den-arbeitgeber-eine- ordnungswidrigkeit-solange-seitens-des-gesundheitsamtes-k/.

Und am 25.1.2022 antwortete die Bundesregierung auf eine parlamentarische Anfrage, ob angesichts des § 20a IfSG mit einer Kündigungswelle im Gesundheitswesen zu rechnen sei, folgendes (Bundestags-Drucksache 20/477, Seite 6 am Ende):

„Die in § 20a des Infektionsschutzgesetzes geregelte einrichtungsbezogene Impfpflicht für Bestandspersonal zieht kein automatisches Beschäftigungsverbot nach sich. Bei Nichtvorlage eines geeigneten Nachweises (Impf- oder Genesenennachweis oder Zeugnis über medizinische Kontraindikation) ist diese zunächst dem Gesundheitsamt zu melden. Bei Nichtvorlage des Nachweises trotz Aufforderung entscheidet das zuständige Gesundheitsamt nach pflichtgemäßem Ermessen im Einzelfall über die weiteren Maßnahmen (z. B. ein Betretungs- oder Tätigkeitsverbot) und wird dabei auch die Personalsituation in der Einrichtung berücksichtigen.“

Ob also das Gesundheitsamt ein solches Betretungsverbot ausspricht, ist nach alledem keinesfalls gesichert; der Erlass eines solchen Verbots liegt vielmehr im Ermessen des Gesundheitsamts. Für die Ausübung dieses Ermessens wird es eine ganz wesentliche Rolle spielen, wie sich der Wegfall von Beschäftigten, die nicht gegen SARS CoV-2 geimpft sind, auf die Beanspruchung der Ressourcen im Gesundheitswesen auswirkt. Es ist mit anderen Worten Ihre Aufgabe als Arbeitgeber, den Gesundheitsämtern klarzumachen, dass sie einen absoluten Notstand bei der Patientenversorgung riskieren, wenn sie von ihren in § 20a IfSG niedergelegten Befugnissen Gebrauch machen. Sie können z. B. darauf verweisen, dass auch die Impfungen Corona-Ausbrüche in Kliniken nicht haben verhindern können. So wurde über einen Ausbruch im Düsseldorfer Universitätsklinikum berichtet:
rp-online.de/…/duesseldorf-corona-ausbruch-an-der-uniklinik_aid- 64044707.

Ebenso im Dietrich-Bonhoeffer-Klinikum in Neubrandenburg:
dbknb.de/…-extern/post/besuchsstopp-in-der-psychiatrie-nach- corona-ausbruch.

Ebenso in einer Reha-Klinik in Wuppertal:
rnd.de/…rtal-corona-ausbruch-in-reha-klinik-aufnahmestopp- angeordnet-4D4HMVNHZWK2VPDROR673AQLXM.html.

Ebenso im Bergmann-Klinikum in Potsdam:
Erneut Corona-Ausbruch im Bergmann-Klinikum bergmannkliniku.html.

Zuletzt im Sana-Klinikum im brandenburgischen Woltersdorf:
moz.de/…lle-an-klinik-corona-ausbruch-im-sana-krankenhaus- woltersdorf_-so-ist-der-aktuelle-stand-61957257.html.

In Großbritannien ist der Notstand so alarmierend, dass in den Kliniken schon das Militär eingesetzt werden muss, um einen halbwegs funktionierenden Betrieb aufrechtzuerhalten:
Aerztezeitung.de Militaer-ein- 425863.html?utm_source=dlvr.it&utm_medium=facebook&fbclid=IwAR1f2XnSw5i2oo4m0Gh6cH8ZZ vFNXoDzPlAe5XXr13zXqnVlGQmwBzFemHI.

All dies haben die COVID-Impfungen nicht verhindern können. Ganz im Gegenteil: Mit großer Wahrscheinlichkeit haben sie die dramatische Situation sogar noch befeuert! Eine Analyse der Statistiken aus 145 Ländern (Beattle, K.: Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A BigData Analysis of 145 Countries, Preprint vom 15.11.2021) mündete in das folgende Ergebnis:
The results of this study taken together demonstrate a product that directly causes more COVID-19 associated cases and deaths than otherwise would have existed with zero vaccines.

Wer sich daran stört, dass diese Studie noch keine Peer Review durchlaufen hat, möge sich im European Journal of Epidemiology vom 30.9.2021 kundig machen: Eine umfassende Datenanalyse in 68 Ländern und 2.947 US-Landkreisen ergab keine Korrelation zwischen der Impfquote und dem Anstieg der COVID-19-Fälle (Subramanian, S.V./Kumar, A., Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States, doi.org/10.1007/s10654-021-00808-7). Damit ist auf breiter Fläche die Nutzlosigkeit der COVID-Impfungen bewiesen.

Aber mehr noch: Unter der Überschrift „Findings“ findet sich die Aussage, dass der Trend sogar eher in die Richtung „höhere Impfquote – mehr Fälle“ ausschlägt. Und in der Tat: Als weiterer Beleg sei auf die folgende in The Lancet veröffentlichte Arbeit verwiesen, in der für eine größere Kohorte von über 60jährigen Menschen festgestellt wurde, dass 89,7% der COVID-Patienten vollständig geimpft waren (Kampf., G, The epidemiological relevance of the COVID-19-vaccinated population is increasing, The Lancet Regional Health – Europe 11 (2021) 100272, doi.org/10.1016/j.lanepe.2021.100272). Die Impfungen nützen also nicht nur nichts – sie machen vielmehr alles noch viel schlimmer!

Sollten, bedingt durch Impfschäden, weitere Mitarbeiterinnen und Mitarbeiter im Gesundheitswesen ausfallen, werden sich auch in Deutschland die Probleme drastisch verschärfen.

Es sollte Ihnen nicht schwerfallen, das Gesundheitsamt davon zu überzeugen, dass Sie weiterhin auf die Arbeitskraft Ihrer ungeimpften Mitarbeiterinnen und Mitarbeiter angewiesen sind. In den USA sind Versuche, die Belegschaften in den Kliniken zwangsweise komplett durchzuimpfen, kläglich gescheitert, weil viele Beschäftigte diesem Zwang trotzten. Die Kliniken mussten klein beigeben und von verpflichtenden Impfungen wieder Abstand nehmen:
USA: Impfpflicht aufgehoben – Amerikas Kliniken droht der Ärzte-Exodus - WELT droht-der-Aerzte-Exodus.html?

Das gleiche wird auch in Deutschland passieren. Auch hierzulande wird das Personal in Scharen dem Gesundheitswesen den Rücken kehren, wenn vom Impfzwang nicht abgelassen wird. Auch in Ihrem Hause droht dann ein Personalnotstand! Setzen Sie daher bitte nicht Ihre Belegschaft unter Druck, sondern die Gesundheitsämter – im Interesse einer zuverlässigen Patientenversorgung!

⦁ Kein Mehrwert durch die COVID-Impfungen

Ein Mehrwert der Impfungen für die Prävention gegen COVID-19-Erkrankungen ist zum gegenwärtigen Zeitpunkt nicht ersichtlich. Denn auch in Deutschland herrscht mittlerweile die Omikron-Variante vor. Ihre Entdeckerin, eine Ärztin aus Südafrika, hat sich entsetzt über die Art und Weise geäußert, wie diese Variante in Europa zum Zweck der Panikmache eingesetzt wird; in Wirklichkeit handelt es sich um eine Variante, die so harmlos erscheint, dass die Chance besteht, auf natürlichem Wege Herdenimmunität zu erreichen, wenn man die Durchseuchung der Bevölkerung mit diesem Erreger einfach zulässt:
focus.de/…virus/aerztin-aus-suedafrika-aerztin-die-variante- entdeckte-wenn-wir-ueberreagieren-laufen-wir-gefahr-die-vorteile-von-omikron-zu- verpassen_id_24536158.html.

Die spanische Regierung hat daraus bereits die Konsequenz gezogen, COVID-19 mit Blick auf Omikron auf den Status einer normalen Grippe herabzustufen:
Spanien behandelt Corona fortan wie eine gewöhnliche Grippe gewoehnliche-

Grippe?utm_content=link_4&utm_medium=email&utm_campaign=dwn_telegramm&utm_source= mid1000&f_tid=dae4aea3cbc7d675e751a8ff0bf80f46.

Diese Vorgehensweise wird gestützt durch die Einschätzung der EMA, dass SARS CoV-2 in der Omikron-Variante endemisch werden könnte, d.h. (spätestens) jetzt der Zeitpunkt erreicht sei, da das menschliche Immunsystem auf breiter Fläche auf den Erreger vorbereitet sei.
Aerztezeitung.de mit-Omikron-infiziert-sein- 425916.html?utm_source=dlvr.it&utm_medium=facebook&fbclid=IwAR3wZUOXY39BJMfp2pu8Mmh ZjbDYFWTiov-rHgcLjGw9Z_Ts5cf0iOtSZHQ.

Je näher wir auf den Zustand zusteuern, dass SARS CoV-2 zum ganz normalen Bestandteil des alljährlichen Infektionsgeschehens wird, desto weniger besteht die Notwendigkeit, einen experimentellen, bis heute nur mit einer bedingten Zulassung ausgestatteten Impfstoff einzusetzen – schon gar nicht mit dem Mittel des Zwangs.

Will man Prävention gegen einen akuten Atemwegsinfekt betreiben (und zwar gleichviel mit welchem Erreger!), besteht eine kostengünstigere und effektivere Möglichkeit allein schon in Gestalt eines ausreichend hohen Vitamin-D-Spiegels. Zahlreiche Studien haben den Nachweis erbracht, dass schwere und tödliche Verläufe von COVID-19 auf diese Weise verhindert werden können. Hier eine Auswahl (weitere Studien werden auf Wunsch gerne nachgereicht):

⦁ Borsche, L.; Glauner, B.; von Mendel, J.: COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis. Nutrients 2021, 13, 3596. doi.org/10.3390/nu13103596.

⦁ Yisak, H. et al.: Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review, Risk Management and Healthcare Policy 2021:14 31–38, doi.org/10.2147/RMHP.S291584.

⦁ Petrelli, F. et al., Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies, Journal of Steroid Biochemistry and Molecular Biology 211 (2021) 105883, doi.org/10.1016/j.jsbmb.2021.105883⦁ .

Wohlgemerkt: Allein schon Vitamin D hat einen hohen prophylaktischen Effekt. Weitere mögliche Optionen der Prophylaxe und der Therapie sind hier noch nicht erwähnt; gerne reiche ich hierzu auf Wunsch ebenfalls zusätzliche Informationen nach.

Wenn Sie Ihre Fürsorgepflicht gegenüber Ihrer Belegschaft wirklich ernst nehmen, werden Sie dies alles gegenüber den Gesundheitsämtern vortragen. Wenn dem Gesundheitsamt an der Vermeidung eines Gesundheitsnotstandes gelegen ist, wird es von Betretungsverboten absehen, und ich kann ganz normal weiterhin meiner Arbeit nachgehen.

⦁ Abschließende Erklärung zum weiteren Vorgehen

Ich fordere Sie hiermit auf, mir gegenüber rechtsverbindlich zu erklären, dass Sie, solange das Ges8undheitsamt kein Betretungsverbot ausspricht, den Bestand meines Arbeitsverhältnisses selbst dann nicht in Frage stellen und mein Arbeitsentgelt selbst dann weiterhin bezahlen werden, wenn ich mich nicht impfen lasse. Ferner erwarte ich von Ihnen, dass Sie alles daran setzen, dass das Gesundheitsamt ein Betretungsverbot gar nicht erst ausspricht. Ich selbst beabsichtige, mich im Falle eines Betretungsverbots gerichtlich dagegen zu wehren.

Sollten Sie diese Erklärung nicht abgegeben, werde ich rechtliche Schritte in Erwägung ziehen, insbesondere die folgenden:

⦁ Im Falle einer Kündigung: Kündigungsschutzklage. Ein Recht zur fristlosen Kündigung steht Ihnen nicht zu. Meine Weigerung, mich impfen zu lassen, lässt sich nicht als Verletzung meiner Pflichten aus dem Arbeitsverhältnis qualifizieren – und zwar allein schon deshalb nicht, weil ich in die Impfung gar nicht mehr wirksam einwilligen kann. Aus dem gleichen Grund scheidet eine verhaltensbedingte Kündigung aus. Und für eine personenbedingte Kündigung ist kein Raum, solange das Gesundheitsamt kein Betretungsverbot ausspricht.

⦁ Im Falle einer unbezahlten Freistellung: Lohnfortzahlungsklage auf der Basis des § 615 BGB sowie Klage auf vertragsgemäße Weiterbeschäftigung. Ich werde meine Arbeitskraft auch in der Zeit nach dem 15.3.2022 ordnungsgemäß anbieten. Und solange das Gesundheitsamt kein Betretungsverbot ausspricht, werden Sie meine Arbeitsleistung annehmen müssen. Solange Sie mir die Zahlung meines Arbeitsentgelts verweigern, werde ich gemäß § 157 Abs. 3 SGB III Arbeitslosengeld I beantragen. Sie müssen dann damit rechnen, von der Agentur für Arbeit in Regress genommen zu werden.

⦁ Einstweilige Verfügung auf Unterlassung weiterer Versuche, mich zur Impfung zu zwingen. Die Anspruchsgrundlage § 823 Abs. 2 BGB i. V. m. §§ 223 ff., 240 StGB trägt nicht nur einen Schadensersatz-, sondern ebenso einen Unterlassungsanspruch. Der Impfdruck verkörpert außerdem zu meinem Nachteil eine vorsätzliche sittenwidrige Schädigung, die gemäß § 826 BGB zu unterlassen ist. Soweit es um die Verletzung meines Körpers geht, stehen mir ferner Unterlassungsansprüche nach § 823 Abs. 1, § 1004 Abs. 1 BGB analog zu. Eine solche Verfügung kann sich gegen jeden richten, der den Impfdruck erzeugt oder aufrechterhält, und damit insbesondere auch gegen Sie persönlich! (Jetzt folgt noch ein Satz für Fälle, in denen Träger der Einrichtung eine OHG, eine KG, GmbH, eine Aktiengesellschaft, eine Genossenschaft oder ein vergleichbarer rechtsfähiger Personenverband ist – bitte füllen Sie also das Nachstehende nur aus und schreiben Sie es nur dann, wenn dies auf Ihren Arbeitgeber zutrifft!) Sie können sich insbesondere nicht dahinter verstecken, dass Sie für eine selbständig rechtsfähige (OHG, KG, GmbH, Aktiengesellschaft, Genossenschaft etc. – bitte das Zutreffende einsetzen) tätig geworden sind. Für den Schaden, den Sie mir durch eine unerlaubte Handlung zufügen, haben Sie vielmehr persönlich geradezustehen. Und deshalb sind Sie auch persönlich unterlassungspflichtig.

Mit freundlichen Grüßen

(Name)

Anlage 1 Impfung im Gesundheitswesen Studienliste Impfnebenwirkungen
Over 1100 scientific studies and/or reports on the dangers associated with COVID injections related to blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre, deaths, etc.

⦁ Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicenter cohort study: ⦁ thelancet.com/journals/lancet/article/PIIS0140- ⦁ 6736(21)01608-1/⦁ fulltext
⦁ Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death following the ChAdOx1 nCoV-19 Vaccine

⦁ Fatal cerebral hemorrhage after COVID-19 vaccine: Fatal cerebral haemorrhage after COVID-19 vaccine - PubMed

⦁ Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: Myocarditis following mRNA vaccination against SARS-CoV-2, a case series

⦁ Three cases of acute venous thromboembolism in women after vaccination against COVID-19: Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019

⦁ Acute thrombosis of the coronary tree after vaccination against COVID-19: Acute Coronary Tree Thrombosis After Vaccination for COVID-19

⦁ US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 - PubMed

⦁ Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: thelancet.com/…ls/langas/article/PIIS2468-1253(21)00197-7/fullte⦁ xt

⦁ Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET) - PubMed

⦁ Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review

⦁ Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines

⦁ Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: Covid-19 vaccine- induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma

⦁ Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines

⦁ COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis

⦁ The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia

⦁ Roots of autoimmunity of thrombotic events after COVID-19 vaccination: Autoimmunity roots of the thrombotic events after COVID-19 vaccination

⦁ Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext

⦁ Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: nejm.org/action/cookieAbsent

⦁ Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

⦁ Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19:

⦁ nejm.org/action/cookieAbsent
⦁
d_article

⦁ Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children - PubMed

⦁ Myocarditis and pericarditis after covid-19 vaccination: Myocarditis and Pericarditis After Vaccination for COVID-19 Mfx7N6RbPK6bYUZ1y8xPnnCK9K5iZYlcEzhX8t68syO5JBwp3w

⦁ Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: ⦁ nejm.org/action/cookieAbsent ⦁ d_article

⦁ Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): Post-mortem findings in vaccine-induced thrombotic thombocytopenia | Haematologica

⦁ Pathological antibodies against platelet factor 4 after vaccination with ChAdOx1 nCoV-19. This article states: “In the absence of previous prothrombotic medical conditions, 22 patients had acute thrombocytopenia and thrombosis, mainly cerebral venous thrombosis, and 1 patient had isolated thrombocytopenia and a hemorrhagic phenotype”: ⦁ nejm.org/action/cookieAbsent &⦁ fbclid=IwA R2ifm2TQjetAMb42YRRUlKEeqCQe-lDasIWvjMgzHHaItbuPbu6n7NlG3cic.

⦁ Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)

⦁ Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID- 19 vaccination: pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478

⦁ Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. ⦁ Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine

⦁ Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

⦁ Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination

⦁ Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data

⦁ Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

⦁ Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)

⦁ Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers

⦁ “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: “Portal vein thrombosis occurring after the first dose of mRNA SARS-CoV-2 vaccine in a patient with antiphospholipid syndrome”

⦁ Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination

⦁ Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination

⦁ Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection

⦁ Prothrombotic immune thrombocytopenia after COVID-19 vaccination: Prothrombotic immune thrombocytopenia after COVID-19 vaccination

⦁ Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story

⦁ Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation

⦁ Thrombosis after COVID-19 vaccination: possible link to ACE pathways: Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways

⦁ Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19

⦁ A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination

⦁ Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – A report of two UK cases

⦁ Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19)

⦁ Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ

⦁ Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: What pathogenesis?

⦁ Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: Recomendaciones diagnóstico-terapéuticas del grupo de trabajo de expertos de FACME ad-hoc sobre el manejo de la trombosis venosa cerebral relacionada con la vacunación frente a COVID-19

⦁ Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure - PubMed

⦁ Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination - PubMed

⦁ Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine - PubMed

⦁ Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine

⦁ COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase - PubMed

⦁ Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: Error - Cookies Turned Off

⦁ Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event - PubMed

⦁ The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination - PubMed

⦁ Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine - PubMed

⦁ Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data - PubMed

⦁ First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland - Nature Medicine

⦁ Exacerbation of immune thrombocytopenia after COVID-19 vaccination: Exacerbation of immune thrombocytopenia following COVID-19 vaccination - PubMed

⦁ First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination - PubMed

⦁ PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: nejm.org/action/cookieAbsent

⦁ Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia - Nature

⦁ Frequency of positive anti-PF4 antibody/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2: Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 ositive-anti-PF4-polyanion-antibody?redirectedFrom=fulltext

⦁ Myocarditis with COVID-19 mRNA vaccines: ahajournals.org/action/cookieAbsent

⦁ Myocarditis and pericarditis after COVID-19 vaccination: Myocarditis and Pericarditis After Vaccination for COVID-19

⦁ Myocarditis temporally associated with COVID-19 vaccination: ahajournals.org/action/cookieAbsent

⦁ COVID-19 Vaccination Associated with Myocarditis in Adolescents: ⦁ pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-

⦁ 053427.full.pdf

⦁ Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19 - PubMed

⦁ Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review

⦁ COVID-19 vaccine-induced myocarditis: a case report with review of the literature: COVID-19 vaccine-induced myocarditis: Case report with literature review

⦁ Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings

⦁ Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent

⦁ Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients
⦁ Acute myocarditis after administration of BNT162b2 vaccine: Acute myocarditis following administration of BNT162b2 vaccine
⦁ Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
⦁ Myocarditis following vaccination with BNT162b2 in a healthy male: Myocarditis after BNT162b2 vaccination in a healthy male
⦁ Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
⦁ Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
⦁ Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
⦁ Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
⦁ Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
⦁ Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age
⦁ Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man
⦁ Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents
⦁ A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2
⦁ Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination
⦁ COVID-19 mRNA vaccination and myocarditis: COVID-19 mRNA Vaccine and Myocarditis - PubMed
⦁ COVID-19 vaccine and myocarditis: COVID-19 Vaccine and Myocarditis - PubMed
⦁ Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study bvsalud.org/…-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.
⦁ COVID-19 vaccines and myocarditis: COVID-19 vaccines and myocarditis - PubMed
⦁ Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines ⦁ Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines ⦁ cardiovascular-comp⦁ lications-of-the-mrna-based-covid-19-vaccines Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines lications-of-the-mrna-based-covid-19-vaccines
⦁ Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination - PubMed
⦁ Myocarditis with covid-19 mRNA vaccines: ahajournals.org/action/cookieAbsent

⦁ Association of myocarditis with COVID-19 mRNA vaccine in children: Association of Myocarditis With mRNA COVID-19 Vaccine in Children - For The Media - JAMA Network vid-19-vaccine-in-children/
⦁ Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: Association of Myocarditis With BNT162b2 Vaccination in Children
⦁ Myocarditis after immunization with COVID-19 mRNA vaccines in members of the
U.S. military: Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
⦁ Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines
⦁ Myocarditis following immunization with Covid-19 mRNA: nejm.org/action/cookieAbsent
⦁ Patients with acute myocarditis after vaccination withCOVID-19 mRNA: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination
⦁ Myocarditis associated with vaccination with COVID-19 mRNA: rsna.org/action/cookieAbsent
⦁ Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID- 19 Vaccination: pediatrics.aappublications.org/content/148/3/e2021052478
⦁ Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: ⦁ https://jcmr- ⦁ Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series - Journal of Cardiovascular Magnetic Resonance
⦁ Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: cps.ca/…s/position/clinical-guidance-for-youth-with-myocar ditis-and-pericarditis
⦁ Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination - PubMed
⦁ Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine
⦁ Myocarditis / pericarditis associated with COVID-19 vaccine: COVID-19 vaccine-associated myocarditis/pericarditis - Science.gc.ca
⦁ Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: lww.com/…Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx
⦁ Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine
⦁ The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism - PubMed
⦁ Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database - PubMed
⦁ Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: Be Alert to the Risk of Adverse Cardiovascular Events after COVID-19 Vaccination
⦁ Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: ahajournals.org/action/cookieAbsent
⦁ In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: ahajournals.org/action/cookieAbsent

⦁ Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? - PubMed
⦁ Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent
⦁ Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction? - PubMed
⦁ Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine - PubMed
⦁ Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report - PubMed
⦁ Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report - PubMed
⦁ Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis? a. ⦁ oup.com/cid/advance- ⦁ article/⦁ doi⦁ /10.1093/⦁ cid⦁ /ciab741/6359059
⦁ Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA- 1237 vaccination: Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination - PubMed
⦁ Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: biomedcentral.com/articles/10.1186/s12872-021-02183
⦁ Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship? - PubMed
⦁ Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis - PubMed
⦁ COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: COVID-19 vaccine induced rhabdomyolysis: Case report with literature review - PubMed .
⦁ GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome – A case report, systemic review and implication for vaccine development
⦁ Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
⦁ Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature
⦁ Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
⦁ Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: Guillain-Barré Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report
⦁ Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: Guillain-Barré syndrome following first injection of ChAdOx1 nCoV-19 vaccine: First report

⦁ SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome

⦁ Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report
⦁ Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database
⦁ Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence?
⦁ New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine
⦁ Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association?
⦁ Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: Bell's palsy and SARS-CoV-2 vaccines—an unfolding story
⦁ Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: bhttps:/⦁ /www.science⦁ direct.com/science/article/pii/S266635462100020X
⦁ Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine
⦁ Bell’s palsy after COVID-19 vaccination: case report: Bell’s palsy following COVID-19 vaccination: a case report
⦁ An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history
⦁ COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan
⦁ ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine
⦁ Late cutaneous reactions after administration of COVID-19 mRNA vaccines: Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19
⦁ COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: COVID-19 vaccine induced rhabdomyolysis: Case report with literature review
⦁ Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study
⦁ Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines .
⦁ COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
⦁ Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non- comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation
⦁ Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
⦁ Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data

⦁ immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
⦁ Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
⦁ COVID-19 RNA-based vaccines and the risk of prion disease: ⦁ scivisionpub.com/…/covid19-rna-based-vaccines-and-the-risk-of-prion- ⦁ disease-1503.pdf
⦁ This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: nejm.org/action/cookieAbsent
⦁ Process-related impurities in the ChAdOx1 nCov-19 vaccine: Process-related impurities in the ChAdOx1 nCov-19 vaccine
⦁ COVID-19 mRNA vaccine causing CNS inflammation: a case series: COVID-19 mRNA vaccination leading to CNS inflammation: a case series - Journal of Neurology
⦁ Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - PubMed
⦁ Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol? - PubMed
⦁ Pfizer Vaccine Raises Allergy Concerns: Pfizer's vaccine raises allergy concerns - PubMed
⦁ Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer- BioNTech COVID-19 vaccine – United States, December 14-23, 2020: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020 - PubMed
⦁ Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021 - PubMed
⦁ Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021 - PubMed
⦁ reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021 - PubMed
⦁ Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: Immunization practices and risk of anaphylaxis: a current update, comprehensive of COVID-19 vaccination data - PubMed
⦁ Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration - PubMed
⦁ Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation - PubMed
⦁ Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) - PubMed
⦁ Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines - PubMed
⦁ Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns - PubMed
⦁ Cutaneous adverse effects of available COVID-19 vaccines: Cutaneous adverse effects of the available COVID-19 vaccines - PubMed

⦁ Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report - PubMed
⦁ COVID-19 vaccines increase the risk of anaphylaxis: [COVID-19 vaccines increase the risk of anaphylaxis] - PubMed
⦁ Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine - PubMed
⦁ Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation - PubMed
⦁ Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine - PubMed
⦁ Acute allergic reactions to COVID-19 mRNA vaccines: Acute Allergic Reactions to mRNA COVID-19 Vaccines - PubMed
⦁ Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2 - PubMed
⦁ Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data - PubMed
⦁ Allergic reactions and adverse events associated with administration of mRNA- based vaccines. A health system experience: Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience - PubMed
⦁ Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): tandfonline.com/action/cookieAbsent e=yacb20.
⦁ IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines - PubMed
⦁ Allergic reactions after COVID-19 vaccination: putting the risk in perspective: Allergic Reactions After COVID-19 Vaccination-Putting Risk Into Perspective - PubMed
⦁ Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study - PubMed 188.
⦁ Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts - PubMed
⦁ COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis - PubMed
⦁ Fatal brain hemorrhage after COVID-19 vaccine: Fatal cerebral haemorrhage after COVID-19 vaccine - PubMed
⦁ A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology - PubMed
⦁ Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases - PubMed
⦁ Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study - PubMed
⦁ Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross- sectional study of 405 cases: Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases - PubMed

⦁ Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry - PubMed
⦁ Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome - PubMed
⦁ Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia - PubMed
⦁ Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea - PubMed
⦁ Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study - PubMed
⦁ Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review - PubMed .
⦁ Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials - PubMed .
⦁ A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration - PubMed
⦁ Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) - PubMed
⦁ Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism - PubMed .
⦁ Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration - PubMed
⦁ 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine - PubMed
⦁ Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience - PubMed
⦁ Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines - PubMed
⦁ Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine - PubMed
⦁ Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination - PubMed
⦁ Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine - PubMed
⦁ Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination - PubMed
⦁ Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: Insights from a murine model of COVID-19 mRNA vaccination-induced myopericarditis: Could accidental intravenous vaccine injection induce myopericarditis? - PubMed

⦁ Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine - PubMed
⦁ propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination - PubMed
⦁ Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination - A Case Report - PubMed
⦁ Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people - PubMed
⦁ COVID-19 vaccination association and facial nerve palsy: A case-control study: Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study - PubMed
⦁ The association between COVID-19 vaccination and Bell’s palsy: The association between COVID-19 vaccination and Bell's palsy - PubMed
⦁ Bell’s palsy after COVID-19 vaccination: Bell's palsy following COVID-19 vaccination - PubMed
⦁ Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19- associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222) - PubMed
⦁ Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine - PubMed
⦁ Sequential contralateral facial nerve palsy after first and second doses of COVID- 19 vaccine: Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses - PubMed
⦁ Transverse myelitis induced by SARS-CoV-2 vaccination: SARS-CoV-2 Vaccination-Induced Transverse Myelitis - PubMed
⦁ Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): Peripheral Facial Nerve Palsy Following BNT162b2 (COVID-19) Vaccination - PubMed
⦁ Acute abducens nerve palsy after COVID-19 vaccination: Acute abducens nerve palsy following COVID-19 vaccination - PubMed .
⦁ Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database - PubMed
⦁ Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273 Vaccine for SARS-CoV-2 Diplopia Following the COVID-19 Vaccine - PubMed
⦁ Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: Bell's palsy following the Ad26.COV2.S COVID-19 vaccination - PubMed
⦁ Bell’s palsy after COVID-19 vaccination: case report: Bell's palsy following COVID-19 vaccination: a case report - PubMed
⦁ A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine - PubMed
⦁ Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: [Guillian Barré syndromeafter mRNA-1273 vaccination against COVID-19] - PubMed
⦁ Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: [Acute facial paresis as a possible complication of vaccination against SARS-CoV-2] - PubMed .
⦁ Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: Bell's palsy following COVID-19 vaccination with high CSF antibody response - PubMed .
⦁ Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: SARS-CoV-2 or SARS-CoV-2 vaccination associated Parsonage-Turner syndrome. Comment on: "Neuralgic amyotrophy and COVID-19 infection: 2 cases of spinal accessory nerve palsy" by Coll et al. Joint Bone Spine 2021;88:105196 - PubMed .

⦁ Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report - PubMed .
⦁ Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID- 19): causality or victim?: Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? - PubMed
⦁ Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: Autoimmune hepatitis triggered by SARS-CoV-2 vaccination - PubMed
⦁ Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? - PubMed .
⦁ Autoimmune hepatitis after COVID vaccine: Auto-immune hepatitis following COVID vaccination - PubMed
⦁ A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination - PubMed
⦁ Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines - PubMed .
⦁ Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination - PubMed
⦁ Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia - PubMed
⦁ Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19 - PubMed
⦁ Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency - PubMed
⦁ Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study - PubMed
⦁ Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data - PubMed
⦁ Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study - PubMed
⦁ First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland - PubMed
⦁ Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany - PubMed
⦁ Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia - PubMed
⦁ celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: Coeliac artery and splenic artery thrombosis complicated with splenic infarction 7 days following the first dose of Oxford vaccination, causal relationship or coincidence? - PubMed .
⦁ Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) - PubMed
⦁ Thrombocytopenia after COVID-19 vaccination: Thrombocytopenia after COVID-19 vaccination - PubMed .

⦁ Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID- 19 vaccination: Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19 - PubMed
⦁ Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: Thrombosis with thrombocytopenia syndrome after COVID-19 vaccination - PubMed
⦁ Acute myocardial infarction within 24 hours after COVID-19 vaccination: Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination - PubMed .
⦁ Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: Bilateral Acute Macular Neuroretinopathy After Vaccination Against SARS-CoV-2 - PubMed
⦁ central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental? - PubMed
⦁ Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea - PubMed
⦁ Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation - PubMed 263.
⦁ Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine - PubMed
⦁ A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 - PubMed
⦁ Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines - PubMed 266.
⦁ Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy - PubMed
⦁ New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine - PubMed
⦁ Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines - PubMed
⦁ Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine - PubMed
⦁ Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration - PubMed .
⦁ Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia - PubMed
⦁ Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV- 2 mRNA vaccine: Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine - PubMed
⦁ Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia - PubMed .
⦁ Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series - PubMed .

⦁ Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis - PubMed .
⦁ Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres - PubMed .
⦁ Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism - PubMed .
⦁ Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal hemorrhage: Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage - PubMed
⦁ Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: Thrombosis of the palmar digital vein after Oxford-AstraZeneca COVID-19 vaccination - PubMed .
⦁ Cutaneous thrombosis associated with cutaneous necrosis following Oxford- AstraZeneca COVID-19 vaccination: Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination - PubMed
⦁ Cerebral venous thrombosis following COVID-19 vaccination: Cerebral Venous Thrombosis following COVID-19 Vaccination - PubMed .
⦁ Lipschütz ulcers after AstraZeneca COVID-19 vaccination: [Lipschütz Ulcers After the AstraZeneca COVID-19 Vaccine] - PubMed .
⦁ Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine - PubMed
⦁ Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine - PubMed
⦁ Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: [Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19] - PubMed
⦁ Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism - PubMed
⦁ Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) - PubMed
⦁ Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites - PubMed
⦁ Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia - PubMed
⦁ Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature - PubMed .
⦁ A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization - PubMed
⦁ Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia-VITT - PubMed
⦁ Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia - PubMed
⦁ Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine - PubMed
⦁ Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia - PubMed
⦁ Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature - PubMed
⦁ Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine - PubMed

⦁ Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination - PubMed
⦁ Post-vaccinal encephalitis after ChAdOx1 nCov-19: Postvaccinal Encephalitis after ChAdOx1 nCov-19 - PubMed
⦁ Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? - PubMed
⦁ Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2Vaccination in Patient with Multiple Myeloma - PubMed
⦁ Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination - PubMed
⦁ Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post- vaccination ASIA syndrome: Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome - PubMed
⦁ Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine - PubMed
⦁ Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study - PubMed
⦁ fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients - PubMed .
⦁ Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST) - PubMed
⦁ Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination - PubMed
⦁ Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: Petechiae and Desquamation of Fingers Following Immunization With BTN162b2 Messenger RNA (mRNA) COVID-19 Vaccine - PubMed
⦁ Hepatitis C virus reactivation after COVID-19 vaccination: a case report: Hepatitis C Virus Reactivation Following COVID-19 Vaccination - A Case Report - PubMed
⦁ Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine - PubMed
⦁ Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female - PubMed
⦁ Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with ChAdO×1 nCov-19 vaccine - PubMed
⦁ Reactive arthritis after COVID-19 vaccination: Reactive arthritis after COVID-19 vaccination - PubMed .
⦁ Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants - PubMed
⦁ Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient - PubMed
⦁ Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination - PubMed
⦁ COVID-19 mRNA vaccine causing CNS inflammation: a case series: COVID-19 mRNA vaccination leading to CNS inflammation: a case series - PubMed
⦁ Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: Thymic hyperplasia after mRNA based Covid-19 vaccination - PubMed

⦁ Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination - PubMed
⦁ Tolosa-Hunt syndrome occurring after COVID-19 vaccination: Tolosa-Hunt Syndrome Presenting After COVID-19 Vaccination - PubMed
⦁ Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-AstraZeneca) vaccination - PubMed
⦁ Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine - PubMed
⦁ Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report - PubMed .
⦁ Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report - PubMed
⦁ Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine - PubMed
⦁ Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford- AstraZeneca): Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine - PubMed
⦁ Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report - PubMed
⦁ Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination - PubMed
⦁ Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: Hemophagocytic lymphohistiocytosis following ChAdOx1 nCov-19 vaccination - PubMed .
⦁ IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19 - PubMed
⦁ A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: Leukocytoclastic Vasculitis After Vaccination With a SARS-CoV-2 Vaccine - PubMed .
⦁ Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases - PubMed
⦁ Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: Exacerbation of Hailey-Hailey Disease Following SARS-CoV-2 Vaccination - PubMed
⦁ Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography - PubMed
⦁ COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem - PubMed .
⦁ Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: The International Cerebral Venous Thrombosis Consortium report on cerebral venous thrombosis following vaccination against SARS-CoV-2 - PubMed
⦁ Immune thrombocytopenia after vaccination during the COVID-19 pandemic: Immune thrombocytopenia following vaccination during the COVID-19 pandemic - PubMed
⦁ COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: COVID-19: Lessons from Norway tragedy must be considered in vaccine rollout planning in least developed/developing countries - PubMed
⦁ Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination - PubMed
⦁ Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases - PubMed

⦁ Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination - PubMed .
⦁ Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature - PubMed
⦁ Vaccine-induced thrombocytopenia with severe headache: Vaccine-Induced Thrombocytopenia with Severe Headache - PubMed
⦁ Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19 - PubMed
⦁ Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis - PubMed .
⦁ Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature - PubMed
⦁ Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
⦁ Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: bmj.com/content/14/5/e242220.abstract⦁ .
⦁ Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine - PubMed
⦁ Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration
⦁ Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
⦁ Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination
⦁ Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: ⦁ Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine &⦁ int_me dium=cpc&int_campaign=usage-042019
⦁ Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination nd-complement-mediated-hematologic?utm_source=TrendMD&utm_medium=cpc &utm_campaign=Blood_Advances_TrendMD_1.
⦁ Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results rendmd&int_medium=cpc&int_campaign=usage-042019
⦁ COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria nduce-severe-hemolysis-in
⦁ Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany - PubMed .
⦁ Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: [Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management] - PubMed
⦁ Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination - PubMed .
⦁ Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases - PubMed .

⦁ Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: SARS-CoV-2 vaccine-induced cerebral venous thrombosis - PubMed .
⦁ Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: Adenovirus…